NCT01737229已完成不适用
Open Trial, Not Randomized Study Evaluating the Efficacy and the Tolerance of RD94 in Patients Needing Endodontic Care, Medical Device Class III
Ascopharm Groupe Novasco3 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2010年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 53
- 试验地点
- 3
- 主要终点
- Efficacy
研究概览
简要总结
TRIAL TITLE Open trial, not randomized study evaluating the efficacy and the tolerance of RD94 in patients needing endodontic care, medical device class III.
SPONSOR:
SEPTODONT, 58 rue de Pont de Créteil, 94107 Saint Maur des Fossés cedex Tel : + 33 1-49-76-74-26, Fax. : + 33 1- 49-76-71-91
Reference protocol: 09/001
PRODUCT NAME: Biodentine™ (RD94)
MEDICAL DEVICE:
Class: Bioactive dental substitute (Tricalcium silicate) Dose: not applicable Application : one single time
DEVELOPMENTAL PHASE: not applicable (medical device class III)
详细描述
METHODOLOGY:
This multi-centre and open-label study comprises six groups corresponding to the six indications tested. No placebo or reference product is involved. No randomization is required as the indication will define the patient selection.
The six indications studied are:
- Direct pulp capping following carious pulp exposure
- Direct pulp capping following dental trauma injury to healthy pulp (partial pulpotomy)
- Repairing perforated root canals and/or the pulp chamber floor
- Retrograde endodontic surgery
- Pulpotomy in primary molars
- Apexification
Study start: October 2009
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •provide signed, informed consent.
- •be affiliated to social security. criteria for the corresponding indication: Direct pulp capping following carious pulp exposure - children (6 to 18 years) + adults
- •Symptomatic or asymptomatic mature or immature tooth that presented pulp exposure when scraping out carious lesions or performing cavity preparation.
- •Direct pulp capping following dental trauma injury to healthy pulp, reformulated as a partial pulpotomy - children (6 to 18 years) + adults
- •Permanent mature or immature single-root tooth having suffered traumatic injury < 72 hours, with amelodentinal coronal fracture causing pulp exposure.
- •Repairing perforated root canals and/or the pulp chamber floor - adults
- •Iatrogenic perforation of the pulpal floor, with or without LEO.
- •Iatrogenic perforated root canals following post space preparation involving dentin matrix, with or without LEO.
- •Iatrogenic perforated root canals with stripping not involving dentin matrix, with or without LEO.
- •Retrograde endodontic surgery - adults
- •Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, provided that a working coronal restoration is in place.
- •Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when orthograde retreatment does not offer a more favorable risk-benefit ratio than the surgery option.
- •Pulpotomy in primary molars - children ( 3 to 12 years )
- •Molar presenting deep carious lesion without irreversible pulpal disease, as the molar has to stay on the dental arch for at least 3 years.
- •Pulp exposure during excision of a carious lesion on a temporary molar that does not present irreversible pulp disease. The molar has to stay of the dental arch for at least 3 years.
- •Apexification - children (7 to 18 years) + adults
- •Permanent immature single-root tooth having suffered periodontal or dentoalveolar injury causing pulp necrosis with or without periapical disease (LEO) in children, teenagers or adult patients.
- •Permanent immature single-root tooth presenting pulp necrosis with or without periapical disease (LEO) in children.
- •Apical Root Resorption
排除标准
- •History of malignancy in the last 5 years.
- •Systemic disease not stabilized within 1 month before the Inclusion Visit or judged by the investigator to be incompatible with the study or condition incompatible with the frequent assessments needed by the study.
- •3 Risk A cardiopathies
- •Known hypersensitivity to one of the components of the study or procedural medications.
- •Presence or history of severe systemic allergy.
- •Presence or history of drug addiction or alcohol abuse.
- •Patient who has participated in a clinical trial with a new active substance during the month before study entry.
- •Participation in another clinical study at the same time as the present study.
- •Known pregnancy or lactation at study entry.
- •exclusion criteria for each indication : Direct pulp capping following carious pulp exposure
- •Chronic irreversible pulpitis
- •Pulp necrosis
- •Anterior or saliva-contaminated tooth pulp exposure
- •Accidental exposure occurring during non-retentive prosthetic preparation Direct pulp capping following dental trauma injury to healthy pulp, reformulated as a partial pulpotomy
- •Pulp exposure period > 72 hours
- •Crown-root fracture
- •Pulpal necrosis with or without periapical disease(LEO)
- •Repairing perforated root canals and/or the pulp chamber floor
- •Supracrestal iatrogenic perforation
- •Inadequate periodontal support
- •Loss of tooth structure (Coronal decay and/or concomitant root decay) compromising the tooth's maintenance on the dental arch) Retrograde endodontic surgery
- •Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, when a working coronal restoration is either missing or presents microleakage
- •Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when surgical treatment does not offer a more favorable risk-benefit ratio than the orthograde retreatment option
- •Insufficient periodontal support, endo-periodontal lesion
- •Coronal decay and/or concomitant root decay compromising the tooth's maintenance on the dental arch
- •Maxillary intrabony lesion of suspected non-endodontic origin
- •Temporary molar expected to begin exfoliation within 24 months.
- •Molar presenting signs of irreversible pulp disease - spontaneous pain
结局指标
主要结局
Efficacy
时间窗: 3 months
The primary objective is to show that RD94 can be easily applied in the claimed indications and to evaluate its efficacy. This can be defined after a 3 month follow-up.
次要结局
- Long term efficacy and safety(2 years)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Faslodex in McCune-Albright SyndromePuberty, PrecociousMcCune-Albright SyndromeNCT00278915AstraZeneca30
已完成
1 期
Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas AeruginosaVentilator Associated PneumoniaPneumoniaNCT00851435Kenta Biotech Ltd15
已完成
3 期
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast CancerBreast Cancer FemaleNCT02980965Fudan University249
进行中（未招募）
不适用
a randomised, open clinical trial to study the efficacy of risedronate 35 mg/week in prevention of bone mass loss and vascular calcifications after kidney transplantationEnsayo aleatorio, abierto para estudiar la eficacia de risedronato 35mg/semanal en la prevención de pérdida de masa ósea y calcificaciones vasculares post-trasplante renal - PREVENOSbone metabolic pathology associated to kidney transplantationMedDRA version: 7.1Level: LLTClassification code 10058972EUCTR2004-002852-33-ESDr. Jose Vicente Torregrosa Prats (fundacio clinic)
尚未招募
2 期
To evaluate effectiveness of Saruva thitha nirgundi thailam for the treatment of throat infection in children.CTRI/2024/06/069475il